Global ETD Search

11	Úloha stabilních analogů peptidu uvolňujícího prolaktin při obezitě a hypertenzi. / The role of stable analogs of prolactin-releasing peptide in obesity and hypertension. Neprašová, Barbora January 2018 (has links) Anorexigenic neuropeptides have the potential to decrease food intake and ameliorate obesity and its complications such as high blood glucose or high blood pressure. However, they are not able to cross the blood-brain barrier after peripheral application. Recently, we have designed and synthesized lipidized analogs of prolactin-releasing peptide (PrRP), which resulted in stabilization of the molecule and allowed us to apply the peptide to the periphery to achieve its central biological effect, as it was demonstrated by increased neuronal activity shown by c-Fos in particular hypothalamus nuclei. The aim of this study was to choose the effective dose in acute food intake experiments and then to characterize the subchronic effect of palmitoylated PrRP analogs in mouse and rat models of obesity and diabetes. Several animal models were used: diet-induced obese (DIO) mice (C57Bl/6J), DIO Sprague-Dawley rats, and two rat models with leptin receptor-deficiency: Zucker diabetic (ZDF) rats and spontaneously hypertensive (SHROB) rats. Consumption of a high-fat diet in DIO mice and rats increased their body weight and blood pressure. Two-week intraperitoneal treatment with palmitoylated PrRP31 lowered the food intake, body weight, and returned the blood pressure to normal levels. This treatment also improved...
12	Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy / Untersuchung von Prolactin-related Vasoinhibin in Sera von Patienten mit diabetischer Retinopathie Triebel, Jakob 11 August 2010 (has links) No description available. 610 Medizin, Gesundheit Medicine Diabetes Mellitus Diabetische Retinopathie Neoangiogenese Neovaskularisation Prolaktin Vasoinhibin Vasoinhibine Retina PRL-Fragmente Diabetes Mellitus Diabetic Retinopathy Neoangiogenesis Neovaskularization Prolactin Vasoinhibin Vasoinhibins Retina PRL-Fragments 44.89 MED 419: Endokrinologie
13	Multiple Sklerose und Dopamin-Rezeptoren / Multiple sclerosis and dopamine receptors Schumacher, Jakob 13 April 2011 (has links) No description available. 610 Medizin, Gesundheit Medicine 44.90
14	Imunogenetické a hormonální predispoziční markery systémových revmatických onemocnění,zejména systémového lupus erythematodu / Immunogenetic and hormonal markers of predisposition to systemic rheumatic diseases particularly systemic lupus erythematosus Fojtíková, Markéta January 2011 (has links) Fojtikova 2011 INTRODUCTION: Several factors like genetic susceptibility is required for systemic rheumatic diseases development. Immunomodulatory PRL effect supports autoimmunity. AIMS: 1. To detect the immunogenetic background (alleles HLA class I, II and microsatellite polymorphism of the transmembrane part exon 5 of MIC-A gene) of SLE and PsA. 2. To detect PRL serum and synovial fluid with regard to clinical and laboratory RA activity. 3. To find the role of the functional polymorphism -1149G/T SNP PRL of extrapituitary promoter of PRL gene in SLE, RA, PsA, SSc and inflammatory myopathies development. METHODS: Genetic analyses of pateints with SLE (n=156), RA (n=173), PsA (n=100), SSc (n=75), PM (n=47) a DM (n=68) and 123 healthy individuals: PCR-SSP (HLA clase I and II), PCR-fragment analysis (MIC-A) a PCR-RFLP (-1149 G/T SNP PRL). In 29 RA a 26 OA PRL serum and synovial fluid concentrations were detected using immunoradiometric assay. RESULTS: 1. The allele HLA-DRB103 (pc=0.008; OR 2.5) and haplotype HLA-DRB103-DQB10201 (pc <0.001; OR 4.54) were determined as risk immunogenetic markers for SLE in Czech population. In SLE versus controls allele MIC-A5.1 was increased (pc =0.005; OR 1.88). MIC-A5.1 together with HLA-DRB103 increases the risk for SLE development, pc <0.000001; OR 9.71....
15	Imunogenetické a hormonální predispoziční markery systémových revmatických onemocnění,zejména systémového lupus erythematodu / Immunogenetic and hormonal markers of predisposition to systemic rheumatic diseases particularly systemic lupus erythematosus Fojtíková, Markéta January 2011 (has links) Fojtikova 2011 INTRODUCTION: Several factors like genetic susceptibility is required for systemic rheumatic diseases development. Immunomodulatory PRL effect supports autoimmunity. AIMS: 1. To detect the immunogenetic background (alleles HLA class I, II and microsatellite polymorphism of the transmembrane part exon 5 of MIC-A gene) of SLE and PsA. 2. To detect PRL serum and synovial fluid with regard to clinical and laboratory RA activity. 3. To find the role of the functional polymorphism -1149G/T SNP PRL of extrapituitary promoter of PRL gene in SLE, RA, PsA, SSc and inflammatory myopathies development. METHODS: Genetic analyses of pateints with SLE (n=156), RA (n=173), PsA (n=100), SSc (n=75), PM (n=47) a DM (n=68) and 123 healthy individuals: PCR-SSP (HLA clase I and II), PCR-fragment analysis (MIC-A) a PCR-RFLP (-1149 G/T SNP PRL). In 29 RA a 26 OA PRL serum and synovial fluid concentrations were detected using immunoradiometric assay. RESULTS: 1. The allele HLA-DRB103 (pc=0.008; OR 2.5) and haplotype HLA-DRB103-DQB10201 (pc <0.001; OR 4.54) were determined as risk immunogenetic markers for SLE in Czech population. In SLE versus controls allele MIC-A5.1 was increased (pc =0.005; OR 1.88). MIC-A5.1 together with HLA-DRB103 increases the risk for SLE development, pc <0.000001; OR 9.71....

Page generated in 0.0508 seconds